Lomefloxacin

Uses and Administration

Lomefloxacin is a fluoroquinolone antibacterial with actions and uses similar to those of ciprofloxacin ( Refer to ).

It is given orally for the treatment of susceptible infections, including bronchitis due toHaemophilus influenzae or Moraxella catarrhalis (Branhamella catarrhalis), and urinary-tract infections. It is also used for surgical infection prophylaxis. Lomefloxacin is given as the hydrochloride but doses are expressed in terms of the base; lomefloxacin hydrochloride 441.5 mg is equivalent to about 400 mg of lomefloxacin. Dosage in the evening may minimise the risk of phototoxic reactions.

The usual dose is 400 mg once daily for 10 to 14 days. A dose of 400 mg once daily for 3 days is suitable in women with acute uncomplicated cystitis. For details of reduced doses in renal impairment, see Refer to .

For surgical infection prophylaxis a single 400-mg dose is given 1 to 6 hours before the procedure.

Lomefloxacin is also used topically as the hydrochloride in eye drops and ear drops containing the equivalent of 0.3% of lomefloxacin for the treatment of bacterial conjunctivitis and for the treatment of otitis externa and otitis media, respectively.

(last reviewed 2010-08-20; last modified 2014-10-17)

General references.

(last reviewed 2010-08-20; last modified 2007-03-09)

References

1. Wadworth AN, Goa KL. Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use.Drugs. 1991; 42: 1018–60. PubMed

2. Neu HC, ed. Lomefloxacin: development of a once-a-day quinolone.Am J Med. 1992; 92 1S–137S. PubMed

Administration in renal impairment

Oral doses of lomefloxacin should be reduced in patients with renal impairment; the initial dose of 400 mg should be followed by maintenance doses of 200 mg daily in those with a creatinine clearance of 10 to 40 mL/minute per 1.73m² and in those on haemodialysis.

(last reviewed 2010-08-20; last modified 2010-07-15)

Adverse Effects, Treatment and Precautions

Adverse Effects and Precautions

As for Ciprofloxacin, Refer to .

A relatively high incidence of phototoxic reactions has been seen in patients taking lomefloxacin. Patients should be advised to avoid exposure to sunlight during, and for a few days after, lomefloxacin therapy, and to stop the drug immediately if phototoxicity occurs. Risk of phototoxicity may be reduced by taking lomefloxacin in the evening.

(last reviewed 2010-08-20; last modified 2008-08-28)

Effects on the skin

Lomefloxacin has been associated with a higher incidence of phototoxic reactions, particularly in patients over 60 years of age and/or with a history of fluoroquinolone treatment; the incidence was also high when used for 30 days or longer.¹In-vitro results² suggest that use of sunscreens to protect against lomefloxacin-induced phototoxicity may be feasible.

(last reviewed 2010-08-20; last modified 2009-10-19)

References

1. Arata J, et al.. Photosensitivity reactions caused by lomefloxacin hydrochloride: a multicenter survey.Antimicrob Agents Chemother. 1998; 42: 3141–5. PubMed

2. Reinhardt P, et al.. Broad-spectrum sunscreens prevent the secretion of proinflammatory cytokines in human keratinocytes exposed to ultraviolet A and phototoxic lomefloxacin.Can J Physiol Pharmacol. 2006; 84: 221–6. PubMed

Interactions

As for Ciprofloxacin, Refer to .

Lomefloxacin does not appear to interact significantly with theophylline or caffeine.

(last reviewed 2010-08-20; last modified 2007-03-12)

Mechanism of Action

Antimicrobial Action

As for Ciprofloxacin, Refer to .

Most streptococci, includingStreptococcus pneumoniae, are relatively resistant to lomefloxacin.

(last reviewed 2010-08-20; last modified 2007-03-09)

Pharmacokinetics

Lomefloxacin is rapidly and almost completely absorbed after oral doses and peak plasma concentrations of about 3 micrograms/mL occur about 1.5 hours after a 400-mg dose. Lomefloxacin is about 10% bound to plasma proteins. It is widely distributed into body tissues including the lungs and prostate.

The elimination half-life of lomefloxacin is about 7 to 8 hours, and is prolonged in patients with renal impairment. Lomefloxacin is excreted in the urine, about 65% as unchanged drug, 9% as the glucuronide, and less than 0.5% as other metabolites. Small amounts (about 10%) are also eliminated unchanged in the faeces. Negligible amounts of lomefloxacin are removed by haemodialysis or peritoneal dialysis.

(last reviewed 2010-08-20; last modified 2009-10-19)

References.

(last reviewed 2010-08-20; last modified 2007-03-09)

References

1. Freeman CD, et al.. Lomefloxacin clinical pharmacokinetics.Clin Pharmacokinet. 1993; 25: 6–19. PubMed

Preparations: Single-Ingredient

The following preparations list represents a compilation of all available salt forms or related substances for this drug product.

The symbol ¤ denotes a preparation which is discontinued or no longer actively marketed.

ARGENTINA: Okacin;AUSTRIA: Okacin¤; Uniquin¤;BELGIUM: Okacin¤;BRAZIL: Maxaquin; Meflox¤; Okacin¤;CHILE: Okacin¤;CHINA: Ai Bang (爱邦); Ao Mei Xin (奥每欣); Bai De (百德); Bai Ye Xing (百夜星); Bei Luo Te (贝洛特); Duo Long (多龙); Fu Yue (孚悦); Ge Tai (哥台); He Le Xin (禾乐新); Ji Ping (吉平); Keqi (科奇); KuiTai (喹泰); Le Bei Xin (乐贝新); Lefen (乐芬); Long Hua Su (龙化素); Luo Wei (洛威); Nuo Ling Dun (诺灵盾); Qi Mi Gao (奇米高); Qian Di (迁迪); Qiluoxian (奇洛先); Qing Xing (庆兴); Shajunda (沙君达); Wanfuluo (万夫洛); Wei Pu (维普); Xin Li Wei (欣立威); Xingfuxin (兴福欣); Yi Lin (逸林); Yi Lu (益禄); Zhen Xin (震欣); Zhong Bao Luo Tai (中宝洛泰); Zhuo Yue (卓悦);CZECH REPUBLIC: Maxaquin¤; Okacin¤;DENMARK: Okacin¤;FINLAND: Okacin¤;FRANCE: Decalogiflox; Logiflox;GERMANY: Okacin¤;GREECE: Okacin¤;HONG KONG: Lomeflox; Maxaquin; Okacin¤;HUNGARY: Okacin¤;INDIA: Floxaday; Foxil; Gynalom; Lomaday; Lomedon; Lomef; Lomewon; Lomexel; Lomflox; Lomibact; Lomitas; Loxipen; Mahaquin; Okacin; Ontop¤;ISRAEL: Maxaquin¤; Okacin¤;ITALY: Chimono; Lomebact; Maxaquin; Okacin; Uniquin;JAPAN: Bareon; Lomebact¤; Lomeflon;MALAYSIA: Lomaday¤; Okacin¤;MEXICO: Lomacin; Maxaquin;PHILIPPINES: Lomecin; Okacin¤;POLAND: Okacin¤;PORTUGAL: Basab¤; Floxaquil¤; Loransil¤; Loxina¤; Maxaquin¤; Monoquin¤; Okacin¤; Uniquin¤;RUSSIAN FEDERATION: Ksenakvin (Ксенаквин); Lofox (Лофокс); Lomacin (Ломацин); Lomflox (Ломфлокс); Maxaquin (Максаквин)¤; Okacin (Окацин)¤;SOUTH AFRICA: Maxaquin¤; Okacyn¤; Uniquin¤;SINGAPORE: Lomflox; Okacin;SPAIN: Ocacin¤;SWITZERLAND: Maxaquin¤; Okacin¤;THAILAND: Maxaquin¤; Okacin¤;TURKEY: Okacin;UNITED ARAB EMIRATES: Lomax;UNITED KINGDOM: Okacyn¤;UKRAINE: Ksenakvin (Ксенаквин)¤; Lomaday (Ломадей); Okacin (Окацин)¤;UNITED STATES: Maxaquin¤;VENEZUELA: Liexina¤; Loflox; Lomaday¤; Lomex; Maxaquin; Okacin;

Preparations: Multi-Ingredient

The following preparations list represents a compilation of all available salt forms or related substances for this drug product.

The symbol ¤ denotes a preparation which is discontinued or no longer actively marketed.

RUSSIAN FEDERATION: Combitub-Neo (Комбитуб-Нео); Lomecomb (Ломекомб); Protiocomb (Протиокомб); Protub-5 (Протуб-5); Protub-Lome (Протуб-Ломе); Vitaprost Plus (Витапрост Плюс);

Therapeutic Use

• Antibacterials

Last Updated 1/21/20